Genesis Drug Discovery & Development (GD3), a member of Genesis Global Group, acquires JSS Medical Research to expand its clinical services portfolio.
Genesis Axis Acquires Organochem to Grow the Preclinical Chemistry Services Portfolio.
Genesis Biotechnology Group Acquires BioBlocks to Grow the Preclinical Chemistry Services Portfolio of Genesis Drug Discovery & Development (GD3)
Nature publishes Bioblocks' collaborative paper presenting fragment-based technology.
View the paper in Nature Communications Read a summary in Chemistry Community
BioBlocks has been awarded a research and innovation grant from the EU’s Horizon 2020 program to expand its Leap-to-Lead™ drug discovery platform
EU Grant Award Press Release
The BioBlocks Leap-to-Lead™ discovery engine is featured in Health Europa Quarterly
BioBlocks, Inc.: Transforming the process of lead discovery
BioBlocks has been awarded a grant from the National Research, Development and Innovation Office of Hungary to support new technology development
Development of a continuous flow photoredox reactor and expansion of a comprehensive fragment library (in Hungarian)
Warren Wade, Vice President of Chemistry, presents a lecture on the design and utility of our Comprehensive Fragment Library (CFL)
Streamlining Drug Discovery Symposium
BioBlocks presents results from recent Leap-to-Lead™ projects at FBLD2018